Literature DB >> 22754660

Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer.

Anne McLeer-Florin, Sylvie Lantuéjoul.   

Abstract

Entities:  

Year:  2012        PMID: 22754660      PMCID: PMC3378206          DOI: 10.3978/j.issn.2072-1439.2012.06.05

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  7 in total

1.  Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.

Authors:  D Ross Camidge; Mariana Theodoro; Delee A Maxson; Margaret Skokan; Tara O'Brien; Xian Lu; Robert C Doebele; Anna E Barón; Marileila Varella-Garcia
Journal:  Cancer       Date:  2012-01-26       Impact factor: 6.860

2.  Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment.

Authors:  D Ross Camidge; Scott A Kono; Antonella Flacco; Aik-Choon Tan; Robert C Doebele; Qing Zhou; Lucio Crino; Wilbur A Franklin; Marileila Varella-Garcia
Journal:  Clin Cancer Res       Date:  2010-11-09       Impact factor: 12.531

3.  KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.

Authors:  Kengo Takeuchi; Young Lim Choi; Yuki Togashi; Manabu Soda; Satoko Hatano; Kentaro Inamura; Shuji Takada; Toshihide Ueno; Yoshihiro Yamashita; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Yuichi Ishikawa; Hiroyuki Mano
Journal:  Clin Cancer Res       Date:  2009-04-21       Impact factor: 12.531

Review 4.  Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer.

Authors:  Hiroyuki Mano
Journal:  Cancer Sci       Date:  2008-11-20       Impact factor: 6.716

5.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

6.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

7.  KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only.

Authors:  Yuki Togashi; Manabu Soda; Seiji Sakata; Emiko Sugawara; Satoko Hatano; Reimi Asaka; Takashi Nakajima; Hiroyuki Mano; Kengo Takeuchi
Journal:  PLoS One       Date:  2012-02-08       Impact factor: 3.240

  7 in total
  9 in total

1.  PIK3CA mutation in Chinese patients with lung squamous cell carcinoma.

Authors:  Jinglin Yu; Hua Bai; Zhijie Wang; Zhigang Wei; Xiaosheng Ding; Jianchun Duan; Lu Yang; Meina Wu; Yuyan Wang; Jie Wang
Journal:  Chin J Cancer Res       Date:  2013-08       Impact factor: 5.087

Review 2.  Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer.

Authors:  Thierry Berghmans; Myriam Remmelink; Ahmad Awada
Journal:  Lung Cancer (Auckl)       Date:  2012-12-17

3.  [Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: Immunohistochemistry and/or FISH?].

Authors:  M von Laffert; P Schirmacher; A Warth; W Weichert; R Büttner; R M Huber; J Wolf; F Griesinger; M Dietel; C Grohé
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

Review 4.  Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic.

Authors:  Ludmila Prudkin; Paolo Nuciforo
Journal:  Cell Oncol (Dordr)       Date:  2014-09-04       Impact factor: 6.730

5.  Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer.

Authors:  Jason N Rosenbaum; Ryan Bloom; Jason T Forys; Jeff Hiken; Jon R Armstrong; Julie Branson; Samantha McNulty; Priya D Velu; Kymberlie Pepin; Haley Abel; Catherine E Cottrell; John D Pfeifer; Shashikant Kulkarni; Ramaswamy Govindan; Eric Q Konnick; Christina M Lockwood; Eric J Duncavage
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

6.  RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.

Authors:  Claudia Vollbrecht; Dido Lenze; Michael Hummel; Annika Lehmann; Markus Moebs; Nikolaj Frost; Philipp Jurmeister; Leonille Schweizer; Udo Kellner; Manfred Dietel; Maximilian von Laffert
Journal:  BMC Cancer       Date:  2018-11-22       Impact factor: 4.430

7.  Discordance between FISH, IHC, and NGS Analysis of ALK Status in Advanced Non-Small Cell Lung Cancer (NSCLC): a Brief Report of 7 Cases.

Authors:  Anna Scattone; Annamaria Catino; Laura Schirosi; Lucia Caldarola; Stefania Tommasi; Rosanna Lacalamita; Elisabetta Sara Montagna; Domenico Galetta; Gabriella Serio; Francesco Alfredo Zito; Anita Mangia
Journal:  Transl Oncol       Date:  2018-12-04       Impact factor: 4.243

8.  Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.

Authors:  Peiyi Xia; Lan Zhang; Pan Li; Enjie Liu; Wencai Li; Jianying Zhang; Hui Li; Xiaoxing Su; Guozhong Jiang
Journal:  J Transl Med       Date:  2021-07-16       Impact factor: 5.531

9.  Competitive Endogenous RNA Network Construction and Comparison of Lung Squamous Cell Carcinoma in Smokers and Nonsmokers.

Authors:  Yan Yao; Tingting Zhang; Lingyu Qi; Ruijuan Liu; Gongxi Liu; Xue Wang; Jie Li; Jia Li; Changgang Sun
Journal:  Dis Markers       Date:  2019-12-04       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.